로딩 중…
지수 로딩 중…
D&D Pharmatech
347850· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩111,200+2.68%
2026-06-19
Price Chart
D&D Pharmatech+211.83%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 4.87T KRW |
| Revenue | 3.01B KRW |
| Net Income | 1.58B KRW |
| Total Assets | 92.50B KRW |
| Net Assets | 73.95B KRW |
| Employees | 24 |
| Value | |
| P/B | 65.87x |
| FCF Yield | -0.44% |
| Profitability | |
| ROE | 2.13% |
| ROA | 1.70% |
| Op. Margin | -1188.29% |
| Revenue Growth | -90.89% |
| Financial Health | |
| Debt Ratio | 125.08% |
| Total Debt | 2.54B KRW |
| FCF | -21.20B KRW |
| Cash | 24.57B KRW |
| Current Ratio | 8.02x |
| Performance | |
| 1Y Return | 211.83% |
| 1M Return | 89.12% |
| From 52W High | -4.63% |
| 1Y MDD | -46.55% |
| Trading | |
| Volume | 2,431,542 shares |
| Foreign Own. | 7.96% |
| Per Share | |
| EPS | -535 KRW |
| BPS | 1,702 KRW |
Company Info
D&D Pharmatech, established in 2014 and listed on KOSDAQ in 2024, holds subsidiaries such as Neuraly Inc., Valted Seq Inc., and P4 Microbiome Inc. The company researches and develops new drugs for metabolic, neurodegenerative, and fibrotic diseases using technologies like GLP-1, with a diverse pipeline including oral obesity treatments. Leveraging new drug development capabilities through drug delivery technology, it advances its business via technology transfer and co-development with global partners. D&D Pharmatech is headquartered in Seongnam-si, Gyeonggi-do.